Show simple item record

dc.contributor.authorJeon, J
dc.contributor.authorOlkhov-Mitsel, E
dc.contributor.authorXie, H
dc.contributor.authorYao, CQ
dc.contributor.authorZhao, F
dc.contributor.authorJahangiri, S
dc.contributor.authorCuizon, C
dc.contributor.authorScarcello, S
dc.contributor.authorJeyapala, R
dc.contributor.authorWatson, JD
dc.contributor.authorFraser, M
dc.contributor.authorRay, J
dc.contributor.authorCommisso, K
dc.contributor.authorLoblaw, A
dc.contributor.authorFleshner, NE
dc.contributor.authorBristow, Robert G
dc.contributor.authorDownes, M
dc.contributor.authorVesprini, D
dc.contributor.authorLiu, S
dc.contributor.authorBapat, B
dc.contributor.authorBoutros, PC
dc.date.accessioned2019-08-05T12:24:48Z
dc.date.available2019-08-05T12:24:48Z
dc.date.issued2019en
dc.identifier.citationJeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, et al. Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome. J Natl Cancer Inst. 2019 Jun 4.en
dc.identifier.pmid31161221en
dc.identifier.doi5510559 [pii];10.1093/jnci/djz112en
dc.identifier.urihttp://hdl.handle.net/10541/621960
dc.description.abstractBACKGROUND: To provide rapid evaluation of patients with advanced urological malignancies, a joint urological-oncological clinic was initiated at our institution in January 2015. We present the first 3-year evaluation of this joint urological-oncological clinic in Switzerland. METHOD: We performed a retrospective analysis of the characteristics and treatment of all patients reviewed at the joint clinic between January 2015 and December 2017. Statistical analysis was performed by survival analysis. A patient satisfaction questionnaire was handed out to new patients (from April to September 2017). RESULTS: A total of 135 new patients were counseled in the joint clinic and 563 consultations were performed in the period from January 2015 to December 2017. The majority were men with prostate cancer (85%), followed by bladder cancer (9%), and renal cell carcinoma (4%). Men with newly diagnosed metastatic prostate cancer (n = 69) received ADT alone (57%), ADT with docetaxel or abiraterone (33%), and metastasis-directed therapy (10%). High rates of patient satisfaction were reported based on the questionnaire. CONCLUSIONS: The joint clinic model has been successfully implemented at our institution and continues on a weekly basis. The clinic is increasingly used, not only for newly diagnosed metastatic prostate cancer, but also for other complex uro-oncological cases. The clinic allows optimized oncological treatment without delay and with a reduced effort for patients.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/5510559 [pii];10.1093/jnci/djz112en
dc.titleTemporal stability and prognostic biomarker potential of the prostate cancer urine transcriptomeen
dc.typeArticleen
dc.contributor.departmentOntario Institute for Cancer Research, Toronto, Canadaen
dc.identifier.journalJournal of the National Cancer Instituteen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record